U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07235306) titled 'Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC' on Sept. 23.
Brief Summary: The PACIFIC study established the standard of care for immunotherapy consolidation after chemoradiotherapy (CRT) in patients with unresectable stage III non-small cell lung cancer (NSCLC). However, its benefit is limited in patients with driver gene mutations. The LAURA study established a new paradigm of targeted consolidation therapy after CRT for patients with EGFR mutations. Although retrospective data support the efficacy of ALK-TKIs, no randomized controlled trial (RCT) has clearly demonstrated the value of ALK-TKI maintenance therap...